NCCN Guidelines®: Melanoma - Treatment of Recurrent or Progressive Distant Metastatic Melanoma

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

Target Audience

This educational program is designed to meet the educational needs of physicians (medical, surgical, and radiation oncologists); nurses; physician assistants; pharmacists; and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify the factors to consider when selecting systemic therapy for a patient with previously treated metastatic melanoma.
  • Individualize the management of patients with metastatic melanoma and select treatment options that are consistent with the NCCN Guidelines® for Melanoma.
  • Explain to patients the data supporting the recommended treatment options for previously treated metastatic melanoma.
Additional information
Supporters: 

This activity is supported by an educational grant from:

  • Astellas
  • AstraZeneca
  • Biocompatibles, Inc. (BTG)
  • Celgene Corporation
  • Genentech
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • Pfizer
  • Prometheus Laboratories Inc.
  • Sanofi Genzyme
  • Taiho Oncology

This activity is supported by an independent educational grant from AbbVie; Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte; and Merck & Co., Inc.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

This activity is supported by educational funding provided by Amgen.

Course summary
Available credit: 
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.48 ANCC contact hours
  • 0.50 Participation
Course opens: 
05/15/2018
Course expires: 
03/01/2019
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™

April K. Salama, MD
Duke Cancer Institute

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
April K. Salama, MD
*AbbVie Grant/Research Support
Array: Scientific Advisor
Biocryst: Consulting Fees, Honoraria
Bristol-Myers Squibb Company: Consulting Fees, Honoraria; Grant/Research Support; Product/Speakers Bureau
Celldex: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Immunocore: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Reata: Grant/Research Support

*signifies the relationship relates to the individual's spouse/partner

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA; Heather Matt; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio, MS; Liz Rieder; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017); Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity Interest/Stock Options

Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Anita M. Engh, PhD; Nicole R. McMillian, MS, CHES

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.50 hours of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.48 contact hours.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.50 contact hours (0.050 CEUs) of continuing education credit. UAN: 0836-0000-18-084-H01-P

Available Credit

  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.48 ANCC contact hours
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: